These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 32799584)

  • 21. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
    Song J; Li X; Ni J
    Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
    Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
    Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 29. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
    Shah N; Perkovic V; Kotwal S
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.
    Gan T; Song Y; Guo F; Qin G
    Mol Biol Rep; 2022 Nov; 49(11):10915-10924. PubMed ID: 36002651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?
    Morillas C; D'Marco L; Puchades MJ; Solá-Izquierdo E; Gorriz-Zambrano C; Bermúdez V; Gorriz JL
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34070103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Stephens JW; Brown KE; Min T
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
    Kashihara N; Kidokoro K; Kanda E
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic Kidney Disease.
    Bonner R; Albajrami O; Hudspeth J; Upadhyay A
    Prim Care; 2020 Dec; 47(4):645-659. PubMed ID: 33121634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiorenal Protection in Diabetic Kidney Disease.
    Lee JF; Berzan E; Sridhar VS; Odutayo A; Cherney DZI
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):256-269. PubMed ID: 33873265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.